Real-world evidence (RWE) is increasingly important to clinicians, regulators and payers
- Regional and local registries are a valuable source of RWE
- The large Corrona RA US registry has revealed information revenant to clinical practice (e.g. non-adhearance, effectiveness and safety of biologics, orals and DMARDs, quality of life)
- RWE complements data from clinical trials
Several challenges remain in the treatment of RA
- Many patients do not take MTX as prescribed due to side effects or inadequate response
- Reimbursement barriers in some countries may reduce patients’ chances of achieving clinical remission
- Reliable biomarkers are needed to identify patients who would benefit from earlier biologic treatment
New approaches to treating RA are being developed
- Considerable unmet medical need remains in DMARD-IR and TNF-IR RA patients
- Breakthroughs in immunology are demystifying the heterogeneity of RA
- Advances in protein engineering and precision combination treatment approaches to restore immune homeostasis may help achieve improved remission rates and safety
- Roche is continuing its longstanding commitment to address unmet needs in rheumatic diseases
“RWE helps us create a bigger picture of what really happens to patients” — Prof Leslie Harrold
Read More…
http://www.eularcongressnews-digital.com/eularcongressnews/eular_2017_re…